Ampio Pharmaceuticals, Inc.

236 articles with Ampio Pharmaceuticals, Inc.

• Ampio Begins Phase 1 Clinical Trial of Inhaled Ampion For COVID-19 Patients With Respiratory Distress

  10/28/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today the Company has begun recruiting and enrolling patients in a Phase I multi-center, randomized, controlled trial for a total of 40 patients that will assess the safety and efficacy of inhaled Ampion

• Ampio Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event "COVID-19 Therapeutics in Development"

  10/27/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it will present at the ROTH Capital Healthcare Event, "COVID-19 Therapeutics in Development" taking place on Wednesday, October 28, 2020 – 9:00 AM (ET) / 6:00 AM (PT).

• Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities

  10/26/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the Company will present at the 2020 MedTech Innovation Forum hosted by Roth Capital Partners on Wednesday, October 28, 2020.

• Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation

  10/8/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the publication of a scientific manuscript on Ampion™ effects on peripheral blood monocytes ("PBMC") in a preprint report (Ampion suppresses cytokine release by modulating select inflammatory transcription factor activity in stimulated PBMC, DOI: https://doi.org/10.21203/rs.3.rs-86515/v1).

• FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress

  9/21/2020

   Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") announces the receipt of an Investigational New Drug ("IND") from the U.S. Food and Drug Administration ("FDA"), allowing the Company to proceed with clinical trials for the use of Ampion TM  as an inhalation therapy for respiratory distress due to COVID-19 infec

• Ampion Phase I COVID-19 Patient Trial Results Featured on FOX News (Video)

  9/14/2020

   Ampio Pharmaceuticals, Inc. (NYSE American: AMPE),  today announced that Michael Roshon, MD, PhD, Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado, who served as Principal Investigator of the just completed Phase I trial of intravenous Ampion

• Ampio Reports Positive Results for Ampion Treatment in COVID-19 Patients

  9/9/2020

  - Ampion-treated patients showed improvement from severe disease/hospitalization to uninfected/ambulatory on the ordinal scale - Ampion-treated patients showed greater improvement compared to patients treated with the standard of care including anti-viral therapies - Ampion found to be safe and well-tolerated with no drug related adverse events

• Ampio Announces Enrollment Completion for Intravenous ("IV") COVID-19 Clinical Trial & Provides Update on Osteoarthritis of the Knee ("OAK") Clinical Trial

  9/4/2020

   Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following: 

• Ampio Provides Update on COVID-19 Clinical Trial Activities

  8/19/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, provides updates regarding the following clinical trials:

• Ampio Starts Patient Enrollment in its Ampion COVID-19 Program

  7/23/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio"), is a biopharmaceutical company focused on the development and advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is actively working on the development of therapies for patients infected wi

• Ampio Reports a Publication on the Potential Benefits of Ampion for Treatment of a New COVID-19 related Syndrome

  7/20/2020

   Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development and advancement of immunology based therapies for prevalent inflammatory conditions, today announced the publication "Insights into pediatric multi-system inflammatory syndrome and COVID-19."

• Ampio to Start First Clinical Trial in COVID-19 Program

  6/19/2020

   Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company") ,  is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the Company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").

• Ampio Provides Update on COVID-19 Program

  5/22/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) is a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions. As part of this program, the company is developing therapies for patients infected with the SARS-CoV-2 virus ("COVID-19").

• Ampio Reports Acceptance of Publication on the Potential Benefits of Nebulized Ampion™ for COVID-19 Patients

  5/11/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the development of immunology based therapies for prevalent inflammatory conditions, today announced a manuscript accepted for publication in The Journal of Patient Safety in Surgery that showed Ampion treatment could improve clinical outcome

• Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

  4/2/2020

  Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat prevalent inflammatory conditions announced today that it was featured on a FOX segment titled, " Englewood pharmaceutical company looking to treat COVID

• Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

  3/24/2020

  Ampio Pharmaceuticals, Inc. announced that it is preparing an expanded access FDA protocol to study potential benefit of nebulized treatment with Ampion in SARS-Cov-2 induced Acute Respiratory Distress Syndrome, an immediately life-threatening condition.

• Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

  3/24/2020

  Ampio Pharmaceuticals, Inc., a pre-revenue development stage biopharmaceutical company announced that it has suspended patient enrollment in its Phase 3 clinical trial of Ampion for the treatment of severe osteoarthritis of the knee.

• Ampio Provides Corporate Update - Feb. 21, 2020

  2/21/2020

  Ampio Pharmaceuticals, Inc. announced updates regarding the continued progress of its Phase III AP-013 clinical trial and receipt of its annual audit opinion.

• 

  Clinical Catch-Up: December 2-5

  12/9/2019

  It was, as usual, a pretty busy week in clinical trial news. Here’s a look.

• Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

  12/4/2019

  Today announced updates regarding the continued progress of its Phase III AP-013 clinical trial and its manufacturing facility.